Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05965570 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

A Phase 1 study, sponsored by Insmed Incorporated.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target

NCT05965570: Completed Phase 1 study, sponsored by Insmed Incorporated.

NCT05965570 is a Phase 1 study that has completed, run by Insmed Incorporated. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05965570, a Phase 1 study, has completed, sponsored by Insmed Incorporated.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target

Study Summary

The primary purpose of this study is to determine the effect of clarithromycin on the single-dose pharmacokinetics (PK) of brensocatib in healthy participants.

Primary Outcome

The effect of clarithromycin on the single dose pharmacokinetics of brensocatib will be assessed in healthy participants.

Interventions

  • DRUG Clarithromycin
  • DRUG Brensocatib

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2023-07-28
Est. Completion 2023-09-22
Phase Phase 1
Insmed Incorporated

31 total trials

What the finished NCT05965570 record still lists

NCT05965570 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).

The record links to 0 conditions, and to 2 interventions - of which Clarithromycin is the first listed.

NCT05965570 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05965570 about?

NCT05965570 is a clinical study titled "A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants". The primary purpose of this study is to determine the effect of clarithromycin on the single-dose pharmacokinetics (PK) of brensocatib in healthy participants.

What is the current status of trial NCT05965570?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2023-07-28. Estimated completion is 2023-09-22.

What interventions are being tested in trial NCT05965570?

The interventions under investigation include: Clarithromycin (DRUG), Brensocatib (DRUG).

Who is sponsoring clinical trial NCT05965570?

This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05965570's enrollment target sits among peer trials

22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05965570, the US trial registry maintained by the National Library of Medicine. NCT05965570 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.